Clinical Trial

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Name: Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS — clinical trial record (NCT07435038)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-25.

Trial Details

NCT Number	NCT07435038
Lead Sponsor	Betta Pharmaceuticals Co., Ltd.
Conditions	Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Enrollment	120 participants
Start Date	2026-02-12
Primary Completion	2028-12-28 (estimated)
Study Completion	2029-10-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-11